Chris Doughty has served as chief business officer of Crescent since October 2024. Mr. Doughty previously was chief business officer of Prometheus Biosciences, serving in the role through its acquisition by Merck for $10.8 billion in 2023. He also served as vice president of strategy and business development at Strata Oncology, after working as a consultant at McKinsey & Company. Mr. Doughty earned an MBA and a BS in industrial and operations engineering from the University of Michigan.